产品
编 号：F008854
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1018448-65-1
产品详情
生物活性：
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer.
体内研究：
Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice.Animal Model:CB-17/SCID mice (6 weeks) were injected with OVA10 cells
Dosage:15 mg/kg
Administration:I.v. three to five times weekly for 3 weeks
Result:Showed remarkable inhibition of tumor growth in mice and was well tolerated.
体外研究：
Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells.
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer.
体内研究：
Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice.Animal Model:CB-17/SCID mice (6 weeks) were injected with OVA10 cells
Dosage:15 mg/kg
Administration:I.v. three to five times weekly for 3 weeks
Result:Showed remarkable inhibition of tumor growth in mice and was well tolerated.
体外研究：
Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备